Immunogenicity of BNT162b2 vaccine booster against SARS-CoV-2 Delta and Omicron variants in nursing home residents: A prospective observational study in older adults aged from 68 to 98 years

• Main Authors: Enagnon Kazali Alidjinou (Author), Julie Demaret (Author), Bénédicte Corroyer-Simovic (Author), Julien Labreuche (Author), Anne Goffard (Author), Jacques Trauet (Author), Daniela Lupau (Author), Sophie Miczek (Author), Fanny Vuotto (Author), Arnaud Dendooven (Author), Dominique Huvent-Grelle (Author), Juliette Podvin (Author), Daniel Dreuil (Author), Karine Faure (Author), Dominique Deplanque (Author), Laurence Bocket (Author), Alain Duhamel (Author), Annie Sobaszek (Author), Didier Hober (Author), Michael Hisbergues (Author), Francois Puisieux (Author), Brigitte Autran (Author), Yazdan Yazdanpanah (Author), Myriam Labalette (Author), Guillaume Lefèvre (Author)
• Format: Book
• Published: Elsevier, 2022-06-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Summary: Background: The present study aimed to evaluate the persistent immunogenicity offered by a third dose of BNT162b2 against Delta and Omicron variants, in nursing home (NH) residents. Methods: In this monocenter prospective observational study, anti-spike IgG levels, S1 domain reactive T cell...